Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Phase 4

1(33.3%)

N/A

1(33.3%)

Phase 2

1(33.3%)

3Total

Phase 4(1)

N/A(1)

Phase 2(1)

Loading network data...

Showing 5 of 5 trials

Efficacy and Safety of Yishen Daluo Yin Granule for Relapsing-Remitting Multiple Sclerosis

Role: lead

Effectiveness of the Combination Strategy of Disease-Modifying Therapy and the Yishen Daluo Yin Modified Formula for Multiple Sclerosis

Role: lead

Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke

Role: lead

Analyzing the Pharmacodynamic Substances and the Effects of Yiqihuayu Decotion for Acute Ischemic Stroke (PHYSIS)

Role: lead

Analyzing the Pharmacodynamic Substances and the Effects of Xingnaojing for Mild-to-Severe Acute Ischemic Stroke

Role: lead

All 5 trials loaded